
You are here
International scientific guidelines adopted in Australia
Related information
The TGA closely aligns its regulatory approaches to therapeutic products with those of comparable international regulatory counterparts wherever possible.
Technical data requirements for applications to register or vary the registration of medicines in Australia are closely aligned with requirements set out in relevant:
- European Union (EU) Guidelines
- Guidelines issued by the International Conference on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use
- Food and Drug Administration (USA)
International Guidelines are not limited to prescription medicines, but may also apply to OTC, complementary and some listed medicines. It is important that you review the relevant guidelines that are adopted in Australia prior to manufacturing and supplying a medicine.
While guidelines that are adopted in Australia are generally not mandated by legislation, they provide guidance to sponsors to assist them to meet the legislative requirements and any deviation from a Guideline relevant to an application to register or vary the registration of a medicine must be justified.
Prior to adopting any Guideline, the TGA undertakes an extensive process of internal and external consultations to ensure the Guideline is consistent with prevailing requirements in Australia. TGA publishes a searchable list of International Guidelines adopted in Australia. Please check for current consultations on proposed guidelines for adoption in Australia.
Please note: Where EU Guidelines adopted in Australia include references to EU legislation (including EC Directives and Regulations), the requirements contained in the referenced EU legislation are not applicable to the evaluation of medicines by the TGA.
International scientific guidelines adopted in Australia
Displaying 61 - 70 of 373
Overseas effective date: 15 Sep 2014
Guideline on pharmaceutical development of medicines for paediatric use
Categories: Quality | Pharmaceutical development (quality)
Overseas effective date: 1 Dec 2014
Addendum to EMA/CHMP/CVMP/QWP/17760/2009 Rev 2: Defining the Scope of an NIRS Procedure
Categories: Quality | Specifications and analytical procedures and analytical validation
Overseas effective date: 17 Jun 2015
Guideline on the quality of transdermal patches
Replaces: CPMP/QWP/604/96. Note for Guidance on Quality of Modified Release Products: [B: Transdermal Dosage Forms] (adopted by TGA April 2001)
Categories: Quality | Specific types of products
Overseas effective date: 1 Oct 2006
Guideline on the Pharmaceutical Quality of Inhalation and Nasal Products
Categories: Quality | Specific types of products
Overseas effective date: 1 May 2000
Note for Guidance on Manufacture of the Finished Dosage Form
Categories: Quality | Manufacturing
Overseas effective date: 25 May 2015
Guideline on stability testing for applications for variations to a marketing authorisation
Categories: Quality | Stability
Overseas effective date: 31 Jan 2015
Guideline on quality of oral modified release products
Replaces: CPMP/QWP/604/96 Note for Guidance on Quality of Modified Release Products: [A: Oral Dosage Forms] (Adopted by TGA 19 April 2001)
Categories: Quality | Specific types of products
Overseas effective date: 28 May 2010
Guideline on Excipients in the Dossier for Application for Marketing Authorisation of a Medicinal Product
Replaces: 3AQ9a and CPMP/CVMP/QWP/115/95
Categories: Quality | Excipients
Overseas effective date: 22 Jun 2009
Guideline for Radiopharmaceuticals
Categories: Quality | Specific types of products
Overseas effective date: 4 Jan 2006
Guideline on summary of requirements for Active Substances in the quality part of the dossier
Replaces: CHMP/QWP/297/97 (Adopted by TGA 12 February 2003)
Categories: Quality | Active substance